Analyzing Apollo Endosurgery (APEN) and Its Peers

Apollo Endosurgery (NASDAQ: APEN) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Apollo Endosurgery to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of recent ratings and recommmendations for Apollo Endosurgery and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollo Endosurgery 0 0 4 0 3.00
Apollo Endosurgery Competitors 494 1889 3757 118 2.56

Apollo Endosurgery currently has a consensus price target of $10.25, suggesting a potential upside of 74.91%. As a group, “Surgical & medical instruments” companies have a potential upside of 12.78%. Given Apollo Endosurgery’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Apollo Endosurgery is more favorable than its rivals.

Profitability

This table compares Apollo Endosurgery and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apollo Endosurgery -42.35% -64.48% -27.44%
Apollo Endosurgery Competitors -62.26% -47.35% -18.28%

Earnings & Valuation

This table compares Apollo Endosurgery and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Apollo Endosurgery $64.31 million -$27.29 million -2.92
Apollo Endosurgery Competitors $1.54 billion $111.80 million -145.41

Apollo Endosurgery’s rivals have higher revenue and earnings than Apollo Endosurgery. Apollo Endosurgery is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Apollo Endosurgery has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Apollo Endosurgery’s rivals have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

31.2% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 52.8% of Apollo Endosurgery shares are owned by insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Apollo Endosurgery rivals beat Apollo Endosurgery on 7 of the 12 factors compared.

About Apollo Endosurgery

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply